Curis (CRIS) Stock Price

Curis Price

NASDAQ·CLOSED
0.75
​
Market closed

Revenue at Curis has contracted by 2.4% per year over the past 19 years to 9.44 M USD. For Curis, the net margin of -80.3% is up versus -426.7% a few years ago.

Curis stock price

Access this data via the Eulerpool API

Curis business model & stock analysis

Curis Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Lexington, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2000-08-01. Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The firm conducts its research and development programs both internally and through strategic collaborations.

Frequently asked questions about Curis

10 analysts currently rate the Curis stock: 9 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Curis share trades at 0.67 EUR (0.75 USD).

The Curis share (CRIS) is listed on 3 stock exchanges, including: NASDAQ (CRIS), Frankfurt (CUS0.F), München (CUS0.MU).

The revenue cannot currently be calculated for Curis.

The expected profit of Curis is -307.43 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Curis is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Curis stock.

The P/S cannot be calculated for Curis currently.

The Eulerpool Quality Score for Curis is 2/10.

The ISIN of Curis is US2312693094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Curis is A3ETJD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Curis is CRIS. The ticker symbol is used to trade Curis shares on the stock exchange.

Fair ValueTerminal
0.63 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
185,156.86 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website curis.com
Currency
USD
Initial public offering
Aug 1, 2000
ISIN
US2312693094
Cusip
231269309
Market capitalization
9.70 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-0.00
P/Ee 2027
-0.01
P/Ee 2028
-0.07
P/Ee 2029
-0.11
P/Ee 2030
-1.49
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.78
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-107.09 %
Gross Margin
99.52 %
EBIT Margin
-60.50 %
Net Margin
-80.29 %
EPS (Earnings Per Share)
-9.63 USD
Net Debt / EBIT
0.60
Debt/Equity
0.30
Last updated Oct 5, 2026, 10:33 PM

Curis Peer Group

Curis Ticker

FRANKFURT · CUS0.FMUNICH · CUS0.MUNASDAQ · CRIS

Curis FIGI

CRIS:US · BBG000C1GTC9CRIS:UA · BBG000C1GTJ2CRIS:UC · BBG000C1GVD3CRIS:UN · BBG000C1GW14CRIS:UP · BBG000C1GXN8CRIS:UB · BBG000C1GYK9CRIS:UM · BBG000C1GZB6CRIS:UX · BBG000C1GZH0CRIS:UR · BBG000C1GZR9CRIS:UD · BBG000C1H102CRIS:UF · BBG000C1H399CRIS:VY · BBG000C1H3G1

All fundamentals and in-depth analysis of Curis

Our stock analysis for Curis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Curis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.